Hormone Therapy

//Hormone Therapy

Androgen Deprivation Therapy (ADT) may not be the best way to fight advanced prostate cancer

Researchers from the University and the Sichuan Antibiotics Industrial Institute in China have discovered a novel treatment for advanced prostate cancer. For over forty years, ADT has been the foundation of advanced stage prostate cancer treatment. ADT is effective initially, most often measured by a drop in PSA measurement. But in almost all cases, prostate cancer returns and no longer uses androgen to fuel its growth.  This is called androgen-independent cancer or castration-resistant prostate cancer (CRPC). ADT does not have a significant effect on CRPC.  So, for now, CRPC is barely treatable. So, how are prostate cancer cells converted from androgen-dependent to [...]

By | March 15th, 2017|Advanced Prostate Cancer, Hormone Therapy|0 Comments

Relugolix – New Oral Hormone Treatment

There's a new Phase 3 clinical trial for an oral medication, taken one time per day, that will reduce testosterone for advanced prostate cancer. Myovant Sciences is testing their new drug, called Relugolix in a trial called, HERO. Relugolix lowers testosterone by inhibiting pituitary release of luteinizing hormone and follicle-stimulating hormone. Todays testosterone reducing therapies require injections and the most commonly used such as Lupron start off by raising testosterone and causing a clinical flare of symptoms. Relugolix decreases testosterone within days of initiation and might enable quick  testosterone recovery when treatment ends. That would be super for men thinking abou intermittent therapy. Seek out clinical [...]

By | March 2nd, 2017|Advanced Prostate Cancer, Hormone Therapy|0 Comments

An Easier, Cheaper and More Comfortable Way To Take Zytiga

Rather than taking – and paying – for the full Zytiga dose on an empty stomach, ask your doctor if you could get the same effect from taking just one fourth of your Zytiga dose while enjoying a low-fat or high-fat breakfast. A small phase two study of 36 prostate cancer patients who took 250 mg of Zytiga after a low-fat breakfast had almost the same outcomes as 36 other prostate cancer patients who took the regular 1000mg dose on an empty stomach. These 72 patients were from the United States and from Singapore. Their age rage was from 52 [...]

Ask For a Blood test to identify AR-V7 in Circulating Tumor Cells if you are starting Xtandi or Zytiga

One of the hot topics in the prostate cancer community is the value of detecting AR-V7 tumor cells circulating in the blood. AR-V7 tumor cells in the blood predicts response or failure of treatment with enzalutamide (Xtandi) or abiraterone (Zytiga). A recent study found that men who have AR-V7 circulating tumor cells in their blood will not respond to Xtandi or Zytiga and will live longer if treated with a taxane based chemotherapy (docetaxel) regimen. A study in JAMA Oncology, showed that evaluating for the presence of circulating tumor cells (CTCs) with AR-V7 could optimize treatment protocols. The study looked at 161 men with progressing metastatic castration-resistant [...]